<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Amiodarone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01118</strong>&#160; (APRD00288)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01118/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01118/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01118.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01118.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01118.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01118.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01118.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01118">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Amiodarona</td><td>Spanish</td><td>INN</td></tr><tr><td>Amiodaronum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Amiodarone Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000355/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000355/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ITPDYQOUSLNIHG-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 681.000358378</li>
              <li>Average Mass: 681.773</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000355">DBSALT000355</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Amio-Aqueous IV</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aratac</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Arycor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Atlansil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Cordarone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nexterone</td><td>Baxter Healthcare Corporation</td></tr><tr><td>Pacerone</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tachyra</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>1951-25-3</td></tr><tr><th>Weight</th><td>Average: 645.3116<br>Monoisotopic: 645.023680639</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>29</sub>I<sub>2</sub>NO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IYIKLHRQXLHMJQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Stilbenes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Stilbenes</td></tr><tr><th>Alternative parents</th><td>Acetophenones; Benzofurans; Phenol Ethers; Benzoyl Derivatives; Alkyl Aryl Ethers; Iodobenzenes; Aryl Iodides; Furans; Tertiary Amines; Ketones; Enolates; Polyamines; Organoiodides</td></tr><tr><th>Substituents</th><td>acetophenone; benzofuran; phenol ether; benzoyl; iodobenzene; alkyl aryl ether; benzene; aryl iodide; aryl halide; furan; ketone; tertiary amine; ether; enolate; polyamine; organohalogen; amine; organoiodide; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups  to a phenyl ring lead to stilbenoids.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.</td></tr><tr><th>Pharmacodynamics</th><td>Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.</td></tr><tr><th>Mechanism of action</th><td>The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.</td></tr><tr><th>Absorption</th><td>Slow and variable (about 20 to 55% of an oral dose is absorbed).</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>&gt;96%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Amiodarone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002887" target="_blank">Cytochrome P450 2C8</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00012">N-desethylamiodarone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/12">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.</td></tr><tr><th>Half life</th><td>58 days (range 15-142 days)</td></tr><tr><th>Clearance</th><td><ul>
	<li>90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)]</li>
	<li>100 mL/h/kg [Normal subjects &gt; 65 yrs]</li>
	<li>150 mL/h/kg [younger subjects]</li>
	<li>220 and 440 mL/h/kg [patients with VT and VF]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Intravenous, mouse: LD<sub>50</sub> = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Potassium voltage-gated channel subfamily H member 2<br>Gene symbol: KCNH2<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q12809" target="_blank">Q12809 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>MiRP1</td><td>KCNE2</td><td>Channels formed with mutant MiRP1 subunits and HERG showed slower activation, faster deactivation, and increased drug sensitivity and is associated with cardiac arrhythmia.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/10219239" target="_blank" title='# Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999 Apr 16;97(2):175-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10219239'>10219239 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8615</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.66</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8044</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5099</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7959</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7188</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8948</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8615</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5661
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7696
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6539 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5932
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7638
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Akorn inc</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Bedford laboratories</li>
<li>Ben venue laboratories inc</li>
<li>Bioniche pharma usa llc</li>
<li>Claris lifesciences ltd</li>
<li>Gland pharma ltd</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Hospira inc</li>
<li>International medication systems ltd</li>
<li>Teva parenteral medicines inc</li>
<li>Wockhardt ltd</li>
<li>Wyeth pharmaceuticals inc</li>
<li>Prism pharmaceuticals inc</li>
<li>Apotex corp</li>
<li>Aurosal pharmaceuticals llc</li>
<li>Barr laboratories inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Taro pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Upsher smith laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.alphapharm.com.au">Alphapharm Party Ltd.</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.amphastar.com">Amphastar Pharmaceuticals</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Aurolife Pharma LLC</li>
<li>Aurosal Pharmaceuticals LLC</li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.bionichepharmausa.com">Bioniche Pharma</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.glandpharma.com">Gland Pharma Ltd.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mpirx.com">Murty Pharmaceuticals Inc.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li>Novex Pharma</li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.upsher-smith.com">Upsher Smith Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Amiodarone hcl powder</td><td>38.98USD</td><td>g</td></tr><tr><td>Pacerone 100 mg tablet</td><td>7.58USD</td><td>tablet</td></tr><tr><td>Pacerone 400 mg tablet</td><td>7.43USD</td><td>tablet</td></tr><tr><td>Amiodarone hcl 400 mg tablet</td><td>6.32USD</td><td>tablet</td></tr><tr><td>Cordarone 200 mg tablet</td><td>4.78USD</td><td>tablet</td></tr><tr><td>Pacerone 200 mg tablet</td><td>3.53USD</td><td>tablet</td></tr><tr><td>Amiodarone hcl 200 mg tablet</td><td>3.37USD</td><td>tablet</td></tr><tr><td>Cordarone 200 mg Tablet</td><td>2.32USD</td><td>tablet</td></tr><tr><td>Apo-Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Mylan-Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Novo-Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Pms-Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Ratio-Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Sandoz Amiodarone 200 mg Tablet</td><td>1.3USD</td><td>tablet</td></tr><tr><td>Amiodarone 150 mg/3 ml vial</td><td>0.83USD</td><td>ml</td></tr><tr><td>Pms-Amiodarone 100 mg Tablet</td><td>0.72USD</td><td>tablet</td></tr><tr><td>Amiodarone 900 mg/18 ml vial</td><td>0.59USD</td><td>ml</td></tr><tr><td>Amiodarone 450 mg/9 ml vial</td><td>0.57USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>7635773</td><td>2009-03-13</td><td>2029-03-13</td></tr><tr><td>United States</td><td>5134127</td><td>1993-01-23</td><td>2010-01-23</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>156</td><td>Tondeur, R. and Binon, F.; U.S. Patent 3,248,401; April 26,1966; assigned to Societe
Beige de I'Azote et des Produits Chimiques du Marly, SA, Belgium.</td></tr><tr><td>water solubility</td><td>Low</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>7.57</td><td>AVDEEF,A (1997)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.76e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>7.24</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>7.64</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>42.68</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>145.05</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>56.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p><a href="http://www.drugsyn.org/Amiodarone.htm">DrugSyn.org</a></p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=3248401&amp;tbm=pts" target="_blank">US3248401 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><span class="caps">DELTOUR</span> G, <span class="caps">BINON</span> F, <span class="caps">TONDEUR</span> R, <span class="caps">GOLDENBERG</span> C, <span class="caps">HENAUX</span> F, <span class="caps">SION</span> R, <span class="caps">DERAY</span> E, <span class="caps">CHARLIER</span> R: [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran.] Arch Int Pharmacodyn Ther. 1962 Sep 1;139:247-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14026835">Pubmed</a></li>
	<li><span class="caps">CHARLIER</span> R, <span class="caps">DELTOUR</span> G, <span class="caps">TONDEUR</span> R, <span class="caps">BINON</span> F: [Studies in the benzofuran series. <span class="caps">VII</span>. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran.] Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255-64. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14020244">Pubmed</a></li>
	<li>Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657-67. <a href="http://www.ncbi.nlm.nih.gov/pubmed/5485142">Pubmed</a></li>
	<li>Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/793369">Pubmed</a></li>
	<li>Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV: Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957-64. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6613843">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D02910" target="_blank">D02910 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C06823" target="_blank">C06823 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2157" target="_blank">2157 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507387" target="_blank">46507387 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2072.html" target="_blank">2072 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18957" target="_blank">18957 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=2663" target="_blank">2663 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL633" target="_blank">CHEMBL633 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000496" target="_blank">DAP000496 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448383" target="_blank">PA448383 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=2566" target="_blank">2566 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2566" target="_blank">2566 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2243836" target="_blank">2243836 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/amiodarone.htm" target="_blank">http://www.rxlist.com/cgi/generic/amiodarone.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/amiodarone.html" target="_blank">http://www.drugs.com/amiodarone.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Amiodarone" target="_blank">Amiodarone <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C01BD01<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C01#C01">C01 &#8212; CARDIAC THERAPY</a></li><li><a href="/atc/C01B#C01B">C01B &#8212; ANTIARRHYTHMICS, CLASS I AND III</a></li><li><a href="/atc/C01BD#C01BD">C01BD &#8212; Antiarrhythmics, class III</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:04.04.20</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01118.pdf?1265922797">show</a>(545 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01118.pdf?1265922737">show</a>(51.8 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Amiodarone may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Amiodarone may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Increased risk of cardiotoxicity and arrhythmias.</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Amiodarone may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Amiodarone may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Amiodarone may increase the effect of digoxin.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Increases the effect of quinidine</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic enzyme CYP2C9/10 metabolism, increases effect/level of eltrombopag. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Amiodarone, when used concomitantly with etravirine, may decrease in serum concentration. If possible, monitoring for decreased amiodarone levels is recommended.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Amiodarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. If possible, monitoring of amiodarone levels is recommended. </td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Possible bradycardia, hypotension</td></tr><tr><td><a href="/drugs/DB08868">Fingolimod</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB01195">Flecainide</a></td><td>Amiodarone may increase the effect and toxicity of flecainide</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Amiodarone may increase the effect of fosphenytoin.</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir increases the effect and toxicity of amiodarone</td></tr><tr><td><a href="/drugs/DB01362">Iohexol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may increase the effect and toxicity of amiodarone.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Amiodarone may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Amiodarone may increase serum levels and toxicity of procainamide.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Amiodarone may increase the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Increases the effect of qiunidine</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Possible additive effect on QT prolongation</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of amiodarone</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the effect and toxicity of amiodarone</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Increases roflumilast levels. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone.</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB06402">Telavancin</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Grapefruit and grapefruit juice should be avoided throughout treatment.</li>
<li>Grapefruit can significantly increase serum levels of this product.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>